<DOC>
	<DOCNO>NCT01529671</DOCNO>
	<brief_summary>The purpose study primarily determine safety toleration pharmacokinetics PF-05089771 follow escalate multiple dos last 14 day .</brief_summary>
	<brief_title>A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee</brief_title>
	<detailed_description />
	<criteria>Healthy male subject female subject nonchild bear potential age 18 55 year , inclusive . elderly cohort : healthy male and/or female subject 65 74 year , cohort 3 : subject osteoarthritis knee : Male female subject child bear potential age 18 75 year inclusive time enter study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Treatment investigational drug within 60 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . 12lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec Screening . If QTc exceed 450 msec , QRS exceed 120 msec , ECG repeat two time average three QTc QRS value use determine subject 's eligibility . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . As exception , acetaminophen/paracetamol may use dos â‰¤1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia . Unwilling unable comply Lifestyle guideline describe protocol . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . cohort 3 : Evidence relapse recurrence clinically significant endocrine , metabolic , pulmonary , hepatic , osteomioartricular , gastrointestinal , cardiovascular , renal , , psychiatric neurological disease , neurological disease le 28 day prior screen . Symptomatic OA hip ipsilateral index knee patient considers painful knee . History disease OA may involve index knee last 12 month prior screen , include limited : inflammatory joint disease ( i.e rehumatoid arthritis gout ) , calcium crystal disease , bursitis , tendinitis , tumor cyst , ligament injury , bone fracture , postinfective pathology ; widespread chronic pain condition ( ie , fibromyalgia ) neuropathic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>